Neoflubin (Fludarabine Phosphate)

Fludarabine phosphate, the active ingredient in Neoflubin, is an antimetabolite (purine analog) presented as a sterile intravenous solution for IV use. It is employed in chemotherapy regimens to treat certain hematologic malignancies, particularly chronic lymphocytic leukemia and low‑grade non‑Hodgkin lymphoma.

GNH USA supplies Neoflubin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. Our distribution network ensures consistent quality and regulatory compliance across regions. We adhere to EU GMP standards and provide reliable cold‑chain logistics where required.

Fludarabine phosphate is used in chemotherapy protocols targeting lymphoid malignancies and as part of conditioning regimens for stem cell transplantation. - Chronic lymphocytic leukemia: reduces malignant lymphocyte count and induces remission. - Low‑grade non‑Hodgkin lymphoma: achieves disease control and prolongs survival. - Conditioning for hematopoietic stem cell transplantation: facilitates engraftment by depleting host immune cells.

Fludarabine phosphate may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Myelosuppression: decreased white blood cells, red cells and platelets. - Nausea and vomiting: gastrointestinal upset. - Fatigue: persistent tiredness. - Diarrhea: loose stools that may be watery.

Serious or Rare Side Effects: - Severe infections: opportunistic infections such as Pneumocystis jirovecii pneumonia. - Autoimmune hemolytic anemia: immune‑mediated destruction of red blood cells. - Pulmonary toxicity: interstitial pneumonitis or acute respiratory distress. - Tumor lysis syndrome: rapid tumor cell breakdown causing metabolic disturbances.

When using fludarabine phosphate, careful monitoring and specific precautions are essential. - Monitor blood counts: regular CBC to detect myelosuppression. - Assess renal function: adjust use in renal impairment. - Screen for infections: evaluate for active viral, bacterial, or fungal infections before therapy. - Avoid use in pregnancy: risk to the fetus is unknown; contraindicated unless essential. - Use protective isolation: reduce exposure to opportunistic pathogens during treatment. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Fludarabine phosphate can interact with several medicines; awareness of the interaction level guides clinical decisions.

Major Interactions (Avoid): - Concurrent use with other myelosuppressive agents: may cause severe bone marrow suppression. - Live vaccines: increased risk of infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - Antiviral agents such as ganciclovir: may increase toxicity. - CYP450 substrates: fludarabine may alter metabolism of certain drugs. - Allopurinol: may increase risk of hematologic toxicity.